Yesterday the Chairman of the German Federal Association of the Pharmaceutical Industry (BPI) released a statement expressing concern after Parliament voted significantly against the Government’s proposed Brexit deal. The Chairman stated that both trade and access to medicines must be preserved with a ‘no deal’ scenario threatening to create bottlenecks on both sides.
“Medicines that have been approved for the whole of Europe in the UK, may from now on no longer be sold in Europe. At the same time, pharmaceutical companies trading with the UK must expect chaotic conditions: trade will fall back on WTO rules, including associated tariffs, tariffs and other restrictions.”
“We can only hope that there will not be bottlenecks on both sides. Britain, be it an EU member or not, must therefore ensure that pharmaceutical companies are able to focus on what they are there for: providing medicines for a pan-European healthcare system.”- Dr Martin Zentgraf, Chairman of the BPI